Physician profile
Clem Rodriguez
NPI 1134394034
$618.62
in general payments reported to CMS, 2019-2025
9 companies · $200 in 2025
The $200 reported for 2025 was more than what a typical General Practice provider received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $62.57 · 2022: $203 · 2023: $112 · 2024: $40.74 · 2025: $200.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $353.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $352.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $181.27 | 2022 | |
| Gilead Sciences, INC. | $125.54 | 2025 | Yeztugo |
| Amgen INC. | $78.59 | 2023-2025 | Repatha, Repatha, Otezla |
| Biohaven Pharmaceuticals, INC. | $62.57 | 2021 | |
| Pfizer INC. | $53.99 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $37.87 | 2023-2024 | Xifaxan |
| Viiv Healthcare Company | $33.31 | 2025 | Apretude |
| Novo Nordisk INC | $23.35 | 2024 | Tresiba, Rybelsus, Ozempic |
| Horizon Therapeutics Plc | $22.13 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clem Rodriguez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.